Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors

被引：0
|
作者：
Bahrani, A [1 ]
Hwang, J [1 ]
Malik, S [1 ]
Marshall, JL [1 ]
机构：
[1] Georgetown Univ Hosp, Washington, DC 20007 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3087
引用
收藏
页码：216S / 216S
页数：1
相关论文
共 50 条
  • [1] Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors.
    Moore, DJ
    Bahrani, A
    Hwang, JJ
    Ramzi, P
    Marshall, JL
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (02) : S391 - S391
  • [2] Phase I clinical trial of daily imatinab mesylate (Gleevec) and weekly Paclitaxel in patients with advanced refractory solid tumors.
    Bahrani, A
    Hwang, J
    Egorm, MJ
    Barmen, P
    Ramzi, P
    Marshall, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6252S - 6252S
  • [3] Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors
    Malik, SM
    Moore, DJ
    Hwang, JJ
    Bahrani, A
    McGreivy, J
    Ramzi, P
    Egorin, MJ
    Min, FD
    McDougall, K
    Marshall, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 221S - 221S
  • [4] Phase I clinical trial of pulse dose imatinib (Im) and weekly paclitaxel (P) in patients (pts) with advanced refractory solid tumors.
    Firozvi, KA
    Moore, D
    Min, FD
    Malik, S
    Egorin, M
    Hwang, JJ
    Ramzi, P
    Marshall, JL
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9117S - 9118S
  • [5] A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Michael J. Pishvaian
    Rebecca Slack
    Eunice Y. Koh
    Jan H. Beumer
    Marion L. Hartley
    Ion Cotarla
    John Deeken
    Aiwu Ruth He
    Jimmy Hwang
    Shakun Malik
    Kashif Firozvi
    Minetta Liu
    Beth Elston
    Sandy Strychor
    Merrill J. Egorin
    John L. Marshall
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 843 - 853
  • [6] A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Pishvaian, Michael J.
    Slack, Rebecca
    Koh, Eunice Y.
    Beumer, Jan H.
    Hartley, Marion L.
    Cotarla, Ion
    Deeken, John
    He, Aiwu Ruth
    Hwang, Jimmy
    Malik, Shakun
    Firozvi, Kashif
    Liu, Minetta
    Elston, Beth
    Strychor, Sandy
    Egorin, Merrill J.
    Marshall, John L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 843 - 853
  • [7] Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors
    Bailey, Howard H.
    Alberti, Dona B.
    Thomas, James P.
    Mulkerin, Daniel L.
    Binger, Kimberly A.
    Gottardis, Marco M.
    Martell, Robert E.
    Wilding, George
    CLINICAL CANCER RESEARCH, 2007, 13 (12) : 3623 - 3629
  • [8] Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors
    Ali, Yaqoob
    Lin, Yong
    Gharibo, Mecide M.
    Gounder, Murugesan K.
    Stein, Mark N.
    Lagattuta, Theodore F.
    Egorin, Merrill J.
    Rubin, Eric H.
    Poplin, Elizabeth A.
    CLINICAL CANCER RESEARCH, 2007, 13 (19) : 5876 - 5882
  • [9] Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors
    Tan, Antoinette R.
    Dowlati, Afshin
    Jones, Suzanne F.
    Infante, Jeffrey R.
    Nishioka, Jennifer
    Fang, Lei
    Hodge, Jeffrey P.
    Gainer, Shelby D.
    Arumugham, Thangam
    Suttle, A. Benjamin
    Dar, Mohammed M.
    Lager, Joanne J.
    Burris, Howard A., III
    ONCOLOGIST, 2010, 15 (12): : 1253 - 1261
  • [10] A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors
    Azad, Nilofer
    Perroy, Alyssa
    Gardner, Erin
    Imamura, Chiyo K.
    Graves, Cynthia
    Sarosy, Gisele A.
    Minasian, Lori
    Kotz, Herbert
    Raggio, Miranda
    Figg, William D.
    Kohn, Elise C.
    CANCER BIOLOGY & THERAPY, 2009, 8 (19) : 1800 - 1805
12345